{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:35:04Z","timestamp":1783596904397,"version":"3.55.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bruton tyrosine kinase inhibitors are an effective therapeutic agent for previously untreated patients with chronic lymphocytic leukemia but require indefinite treatment that can result in cumulative toxicities. Novel combinations of agents that provide deep remissions could allow for fixed duration therapy. Acalabrutinib, unlike ibrutinib, does not inhibit anti-CD20 monoclonal antibody-dependent cellular phagocytosis, making it a suitable partner drug to rituximab. Using standard dosing (375\u00a0mg\/m2) of rituximab causes loss of target membrane CD20 cells and exhaustion of the finite cytotoxic capacity of the innate immune system. Alternatively, using high-frequency, low-dose (HFLD), subcutaneous rituximab limits loss of CD20 and allows for self-administration at home. The combination of HFLD rituximab 50\u00a0mg administered twice a week for 6 cycles of 28\u00a0days with the addition of acalabrutinib starting in week 2 was evaluated in a phase II study of 38 patients with treatment naive chronic lymphocytic leukemia. Patients achieving a complete response with undetectable minimal residual disease after 12 or 24 cycles of acalabrutinib could stop therapy. All patient responded, including one with a complete response with undetectable minimal residual disease in the peripheral blood and bone marrow at 12\u00a0months who stopped therapy. At a median follow-up of 2.3 years 2 patients with high-risk features have progressed while on acalabrutinib monotherapy. We conclude that HFLD rituximab in combination with acalabrutinib is an effective and tolerable self-administered home combination that provides a platform to build upon regimens that may more reliably allow for fixed-duration therapy. This trial was registered at www.clinicaltrials.gov #NCT03788291.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009382","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T21:14:13Z","timestamp":1674508453000},"page":"2496-2503","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9371-6777","authenticated-orcid":false,"given":"Danielle S.","family":"Wallace","sequence":"first","affiliation":[{"name":"1Wilmot Cancer Institute and Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-3313","authenticated-orcid":false,"given":"Clive S.","family":"Zent","sequence":"additional","affiliation":[{"name":"1Wilmot Cancer Institute and Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Baran","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[{"name":"1Wilmot Cancer Institute and Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9932","authenticated-orcid":false,"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[{"name":"1Wilmot Cancer Institute and Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Rice","sequence":"additional","affiliation":[{"name":"1Wilmot Cancer Institute and Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"1Wilmot Cancer Institute and Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-401X","authenticated-orcid":false,"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"1Wilmot Cancer Institute and Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"2023061219130448200_bib1","unstructured":"National Cancer Institute. Cancer Stat Facts: Leukemia-Chronic Lymphocytic Leukemia. Accessed 22 August 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"issue":"11","key":"2023061219130448200_bib2","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"2023061219130448200_bib3","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"9747","key":"2023061219130448200_bib4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"2023061219130448200_bib5","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2023061219130448200_bib6","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023061219130448200_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2023061219130448200_bib8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular cytotoxicity of next-generation CD20 monoclonal antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2023061219130448200_bib9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3324\/haematol.2021.279560","article-title":"The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact","volume":"107","author":"Pinney","year":"2022","journal-title":"Haematologica"},{"issue":"10232","key":"2023061219130448200_bib10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"18","key":"2023061219130448200_bib11","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/blood.2020005571","article-title":"Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance","volume":"136","author":"Pinney","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2023061219130448200_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.23737","article-title":"Chemoimmunotherapy for relapsed\/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells","volume":"89","author":"Zent","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"2023061219130448200_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3324\/haematol.2009.012484","article-title":"Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia","volume":"95","author":"Aue","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2023061219130448200_bib14","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/S2352-3026(16)00004-1","article-title":"Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial","volume":"3","author":"Assouline","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"2023061219130448200_bib15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"issue":"25","key":"2023061219130448200_bib16","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2023061219130448200_bib17","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2023061219130448200_bib18","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023061219130448200_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2023061219130448200_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/1078-0432.CCR-15-1304","article-title":"Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy","volume":"22","author":"Skarzynski","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2023061219130448200_bib21","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1158\/1078-0432.CCR-18-1286","article-title":"Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients","volume":"25","author":"Drennan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2023061219130448200_bib22","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.3324\/haematol.2017.169334","article-title":"The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in\u00a0vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies","volume":"102","author":"Golay","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2023061219130448200_bib23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"2023061219130448200_bib24","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood-2022-163387","article-title":"Real-world comparison of time to next treatment for patients with CLL initiated on first-line treatment with ibrutinib versus acalabrutinib","volume":"140","author":"Jacobs","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2023061219130448200_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MLR.0000000000000486","article-title":"Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data","volume":"54","author":"Danese","year":"2016","journal-title":"Med Care"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2496\/2056912\/blooda_adv-2022-009382-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2496\/2056912\/blooda_adv-2022-009382-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T19:13:24Z","timestamp":1686597204000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/11\/2496\/494160\/Acalabrutinib-and-high-frequency-low-dose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009382","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}